Madrigal Pharmaceuticals, Inc. MDGL Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s debt issuance cost amortization?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported debt issuance cost amortization of $449K in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s debt issuance cost amortization changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s debt issuance cost amortization increased by 3.0% year-over-year, from $436K to $449K.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s debt issuance cost amortization?
- Over 3 years (2022 to 2025), Madrigal Pharmaceuticals, Inc.'s debt issuance cost amortization has grown at a 26.3% compound annual growth rate (CAGR), from $797K to $1.6M.
- What does debt issuance cost amortization mean?
- The non-cash expense of spreading debt-related fees over the life of the loan.
- How do you interpret debt issuance cost amortization?
- Changes reflect the company's debt structure and the timing of financing activities.
- How does debt issuance cost amortization compare across companies?
- Standard for companies with significant long-term debt obligations.